Jason Burdick, Robert D. Bent Professor in the Department of Bioengineering, has been named a Fellow of the National Academy of Inventors (NAI), an award of high professional distinction accorded to academic inventors. Elected Fellows have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.
Burdick’s research interests include developing degradable polymeric biomaterials that can be used for tissue engineering, drug delivery, and fundamental polymer studies. His lab focuses on developing polymeric materials for biomedical applications with specific emphasis on tissue regeneration and drug delivery. Burdick believes that advances in synthetic chemistry and materials processing could be the answer to organ and tissue shortages in medicine. The specific targets of his research include: scaffolding for cartilage regeneration, controlling stem cell differentiation through material signals, electrospinning and 3D printing for scaffold fabrication, and injectable hydrogels for therapies after a heart attack.
On the second floor of the Pennovation Center, Strella Biotechnology is hard at work turning their student-led startup into a full-fledged company that’s ready to make a major impact in the agricultural sector.
May graduates Katherine Sizov and Malika Shukurova, respectively the CEO and head of R&D at Strella, share a 2019 President’s Innovation Prize, which includes $100,000 of financial support, a $50,000 living stipend for both awardees, and a year of dedicated co-working and lab space at the Pennovation Center. The alumnae and their company are now poised to take on the challenge of $1 trillion worth of food waste.
Strella’s biosensors are designed to give packers real-time data on how ripe their fruits are while being stored between harvesting and selling. Using bio-inspired sensors that measure the ethylene gas produced by fruits as they ripen, Strella successfully “hacked the fruit” to create their patent-pending biosensors. Now, only six months after graduation, Strella has six paying customers and is aiming for $100,000 in sales by the end of the season.
Beyond the work needed to deploy their first paid product, Strella also has a clear view of what needs to be done for future progress of the company. This means running experiments in the lab to refine their current sensors while conducting other experiments that will help the company be able to monitor other types of fresh foods. It’s a job that Shukurova says involves a lot of multitasking and requires an “all-hands” approach to problem solving.
“We set up experiments that run for several days, and during that period we work on different tasks. I prepare for the next set of experiments, Jacob [Jordan] and Katherine travel to our customers to deploy sensors, and Zuyang [Liu]]works on IoT [Internet of Things]. At the end of the day we all come together to discuss results and future plans,” says Shukurova about their company’s work flow.
Danielle Bassett has been named the J. Peter Skirkanich Professor of Bioengineering.
Dr. Bassett is a Professor in the department of Bioengineering at the School of Engineering and Applied Science. She holds a Ph.D. in Physics from the University of Cambridge and completed her postdoctoral training at the University of California, Santa Barbara, before joining Penn in 2013.
Dr. Bassett has received numerous awards for her research, including an Alfred P Sloan Research Fellowship, a MacArthur Fellowship, an Office of Naval Research Young Investigator Award, a National Science Foundation CAREER Award and, most recently, an Erdos-Renyi Prize in Network Science to name but a few. She has authored over 190 peer-reviewed publications as well as numerous book chapters and teaching materials. She is the founding director of the Penn Network Visualization Program, a combined undergraduate art internship and K-12 outreach program bridging network science and the visual arts.
Last spring, we congratulated Penn Bioengineering graduating senior Oladunni Alomaja (BSE ’19) and her partners at Rebound Liberia on their President’s Engagement Prize. Check out the article and video below on their exciting project.
By Brandon Baker
Fueled by the encouragement and support they received this spring and summer, the three Penn alumni behind Rebound Liberia are now laser-focused on carrying their mission of promoting education and empowerment straight to the basket.
The Rebound Liberia team is led by Princess Aghayere, Oladunni Alomaja, and Summer Kollie, all May Penn graduates who received the President’s Engagement Prize — a $100,000 project prize and $50,000 living stipend per team member, awarded for post-graduation projects that make a positive, lasting difference in the world. The trio, each of whom has connections to West Africa and strives to give back, proposed an NGO that would bridge the literacy gap in post-conflict Liberia between male and female youth through workshops and a basketball program for women.
On Sept. 4, after months of preparation, the team relocated to Monrovia, Liberia, and is settling in.
“I think there’s some cultural shock,” says Aghayere, musing about the adjustment. “But Penn is a great place to travel and a lot of us took advantage of opportunities to travel. I’m not surprised, because this is not my first time on the continent, but there are things unique about Liberia. Getting used to the accents, the weather, the currency — but it’s fun.”
Aghayere and Alomaja were born in Nigeria, while Kollie is from Liberia.
Their days so far, they explain, have been consistently jam-packed with meetings. At present, they’re planning an inter-school basketball tournament to introduce their program to Liberia; in recent weeks, they’ve made connections with school administrators, found their footing in the community, and worked through the logistics of organizing a tournament — which, they note, they had some practice with in 2018, creating a summer basketball clinic in Monrovia, Liberia, for girls that was hosted twice a week.
The upcoming tournament, which will include 120 female players on Nov. 22–24, represents a first step toward their larger intention to build a basketball court and program, and marry that with literacy resources. They aim to serve approximately 60 girls in their program.
“We didn’t think it would be wise to move in September and not have an event until the next June or so, so we thought [of] the tournament,” says Aghayere, explaining the origins of the tournament. “At first, we were thinking we’d have a team and foster the game amongst girls here in Monrovia, and we wanted to include a lot more girls and create this sort of league of our own while introducing ourselves as this new social enterprise in Liberia. We thought a tournament would be a launch of Rebound Liberia and introduce us to the community here.”
Positive results in first-in-U.S. trial of CRISPR-edited immune cells
Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States. Researchers from the Abramson Cancer Center have infused three participants in the trial thus far—two with multiple myeloma and one with sarcoma—and have observed the edited T cells expand and bind to their tumor target with no serious side effects related to the investigational approach. Penn is conducting the ongoing study in cooperation with the Parker Institute for Cancer Immunotherapy and Tmunity Therapeutics.
“This trial is primarily concerned with three questions: Can we edit T cells in this specific way? Are the resulting T cells functional? And are these cells safe to infuse into a patient? This early data suggests that the answer to all three questions may be yes,” says the study’s principal investigator Edward A. Stadtmauer, section chief of Hematologic Malignancies at Penn. Stadtmauer will present the findings next month at the 61st American Society of Hematology Annual Meeting and Exposition.
Because of the opioid epidemic sweeping the nation, Moore notes that there’s a rapid search going on to develop non-addictive painkiller options. However, he also sees a gap in adequate models to test those new drugs before human clinical trials are allowed to take place. Here is where he hopes to step in and bring some innovation to the field, by integrating living human cells into a computer chip for modeling pain mechanisms. Through his research, Moore wants to better understand not only how some drugs can induce pain, but also how patients can grow tolerant to some drugs over time. If successful, Moore’s work will lead to a more rapid and less expensive screening option for experimental drug advancements.
New machine learning-assisted microscope yields improved diagnostics
Researchers at Duke University recently developed a microscope that uses machine learning to adapt its lighting angles, colors, and patterns for diagnostic tests as needed. Most microscopes have lighting tailored to human vision, with an equal distribution of light that’s optimized for human eyes. But by prioritizing the computer’s vision in this new microscope, researchers enable it to see aspects of samples that humans simply can’t, allowing for a more accurate and efficient diagnostic approach.
Led by Roarke W. Horstmeyer, Ph.D., the computer-assisted microscope will diffuse light through a bowl-shaped source, allowing for a much wider range of illumination angles than traditional microscopes. With the help of convolutional neural networks — a special kind of machine learning algorithm — Horstmeyer and his team were able to tailor the microscope to accurately diagnose malaria in red blood cell samples. Where human physicians typically perform similar diagnostics with a rate of 75 percent accuracy, this new microscope can do the same work with 90 percent accuracy, making the diagnostic process for many diseases much more efficient.
Case Western Reserve University researchers create first-ever holographic map of brain
A Case Western Reserve University team of researchers recently spearheaded a project in creating an interactive holographic mapping system of the human brain. The design, which is believed to be the first of its kind, involves the use of the Microsoft HoloLens mixed reality platform. Lead researcher Cameron McIntyre, Ph.D., sees this mapping system as a better way of creating holographic navigational routes for deep brain stimulation. Recent beta tests with the map by clinicians give McIntyre hope that the holographic representation will help them better understand some of the uncertainties behind targeted brain surgeries.
More than merely providing a useful tool, McIntyre’s project also brings together decades’ worth of neurological data that has not yet been seriously studied together in one system. The three-dimensional atlas, called “HoloDBS” by his lab, provides a way of finally seeing the way all of existing neuro-anatomical data relates to each other, allowing clinicians who use the tool to better understand the brain on both an analytical and visual basis.
Implantable cancer traps reduce biopsy incidence and improve diagnostic
Biopsies are one of the most common procedures used for cancer diagnostics, involving a painful and invasive surgery. Researchers at the University of Michigan are trying to change that. Lonnie Shea, Ph.D., a professor of biomedical engineering at the university, worked with his lab to develop implants with the ability to attract any cancer cells within the body. The implant can be inserted through a scaffold placed under the patient’s skin, making it a more ideal option than biopsy for inaccessible organs like lungs.
The lab’s latest work on the project, published in Cancer Research, details its ability to capture metastatic breast cancer cells in vivo. Instead of needing to take biopsies from areas deeper within the body, the implant allows for a much simpler surgical procedure, as biopsies can be taken from the implant itself. Beyond its initial diagnostic advantages, the implant also has the ability to attract immune cells with tumor cells. By studying both types of cells, the implant can give information about the current state of cancer in a patient’s body and about how it might progress. Finally, by attracting tumor and immune cells, the implant has the ability to draw them away from the area of concern, acting in some ways as a treatment for cancer itself.
People and Places
The Philadelphia Inquirer recently published an article detailing the research of Penn’s Presidential Assistant Professor in Psychiatry, Microbiology, and Bioengineering, Cesar de la Fuente, Ph.D. In response to a growing level of worldwide deaths due to antibiotic-resistant bacteria, de la Fuente and his lab use synthetic biology, computation, and artificial intelligence to test hundreds of millions of variations in bacteria-killing proteins in the same experiment. Through his research, de la Fuente opens the door to new ways of finding and testing future antibiotics that might be the only viable options in a world with an increasing level of drug-resistant bacteria
Emily Eastburn, a Ph.D. candidate in Bioengineering at Penn and a member of the Boerckel lab of the McKay Orthopaedic Research Laboratory, recently won the Ashton fellowship. The Ashton fellowship is an award for postdoctoral students in any field of engineering that are under the age of 25, third-generation American citizens, and residents of either Pennsylvania or New Jersey. A new member of the Boerckel lab, having joined earlier this fall, Eastburn will have the opportunity to conduct research throughout her Ph.D. program in the developmental mechanobiology and regeneration that the Boerckel lab focuses on.
Our first seminar in our Penn Bioengineering seminar series will happen shortly after the winter break, so be sure to mark your calendars now!
Speaker: Ning Jenny Jiang, Ph.D.
Associate Professor of Biomedical Engineering
University of Texas at Austin
Date: Thursday, January 9, 2020
Time: 12:00-1:00 pm
Location: Room 337, Towne Building
Title: “High-throughput T Cell Repertoire Profiling Enabled Systems Immunology and Immune Engineering”
T cells are important to the initiation, prevention, and cure of many diseases. For example, various T cells based cancer immunotherapies have been quite effective in treating several types of cancers. However, a significant fraction of patients do not respond. A comprehensive understanding of the complexity of the T cells repertoire in health and diseases not only provide underlying mechanisms but also new therapeutic targets. In the past several years, we have developed several tools to profile the T cell repertoire from T cell receptor diversity to T cell receptor affinity to multi-dimensional profiling of single T cells in high-throughput. In this talk, I will first introduce these tools and then give examples on how we use them to answer some of the fundamental questions in systems immunology, which in turn help us design new approaches in immune engineering.
Dr. Jenny Jiang is an associate professor in the Department of Biomedical Engineering at the University of Texas at Austin. She obtained her Ph.D. from Georgia Institute of Technology and did her postdoc training at Stanford University. Her lab focuses on systems immunology by developing technologies that enable high-throughput, high-content, single cell profiling of T cells in health and disease. Dr. Jiang is a recipient of the prestigious NIH Pathway to Independence Award (K99/R00), Cancer Prevention and Research Institute of Texas, Damon Runyon-Rachleff Innovator Award, NSF CAREER Award, a Chan Zuckerberg Initiative Ben Barres Early Career Acceleration award, and was recently selected as one of National Academy of Medicine 2019 Emerging Leaders in Health and Medicine Scholars.
Cesar de la Fuente, Ph.D., a Presidential Assistant Professor in Psychiatry, Microbiology, and Bioengineering at Penn, recently published a literature review in Trends in Immunology entitled, “Emerging Frontiers in Microbiome Engineering.” The microbiome, in simple terms, consists of the genetic material of microorganisms in the gut, including bacteria, fungi, protozoa, viruses, and oral, vaginal, and skin microbiomes. Each human has a unique microbiome that depends both on predetermined factors like exposure to microorganisms within a mother’s birth canal or breastmilk in early life as well as environmental factors and diet in later life. The health of someone’s microbiome is extremely important, as an unhealthy microbiome with an imbalance of symbiotic and pathogenic microbes can make a person more susceptible to various diseases. The most common diseases or disorders associated with a problematic microbiome are rather far-reaching, including some of the most afflicting diseases of today like inflammatory bowel disease, diabetes, obesity, cardiovascular diseases, and neurological disorders.
In his recent literature review, de la Fuente provides an overview of microbiome engineering, and what the future might hold for the field. He defines microbiome engineering initially as a way of studying the “contribution of individual microbes and generating potential therapies against metabolic, inflammatory, and immunological diseases.” Currently, most treatments for issues with the microbiome are broad solutions like dietary adjustments to include more probiotics, antibiotics, or prebiotics, while more serious cases may require a fecal microbiota transplant. While these therapies may work for some patients, de la Fuente emphasizes the need for greater specificity in treatment targets and a need for precision in reprogramming existing microbial communities as an alternative to transplants.
De la Fuente highlights the current methods and tools in microbiome engineering such as the use of bacteriocins and bacteriophages to knock out specific bacteria within the microbiome. However, there are very few bacteriocins or bacteriophages commercially available on today’s market. Another common approach to microbiome engineering is in synthetic biology, or the use of “chassis” — a type of cell that maintains DNA constructs for different functions — to engineering interactions within the microbiome. De la Fuente continues his discussion of current methods by naming and describing several specific examples of these approaches, particularly in relation to synthetic biology options before moving on to examine future directions for these methods.
Before bringing up potential new frontiers for microbiome engineering, de la Fuente also outlines the way that microbiome engineering works in the first place, and dedicates sections of the review to the microbiome’s influence on its host’s immune system and how to engineer the microbiome to modulate that immune system. The main future methods for microbiome engineering that de la Fuente points out in his review include more precise regulation of gene expression through commensal organisms and the use of CRISPRi to find genes involved in bacterial maintenance. The conclusion of de la Fuente’s review brings up the notion of new personalized medicine or therapy for the microbiome that could come with further advances in the field. However, he also makes sure to bring up some still-outstanding questions about the human microbiome that require further research, most notably, what exactly makes a healthy human microbiome? Here’s hoping the research de la Fuente mentions can illuminate a path to the answer.
When the immune system detects a foreign pathogen, a cascade of chemical signals call white blood cells to the scene. Neutrophils are the most common and abundant type of these cells and while they start accumulating at the site of an infection within minutes, they are essentially at the mercy of the circulatory system’s one-way flow of traffic to get them where they need to go.
Now, research from the University of Pennsylvania’s School of Engineering and Applied Science shows how these cells can be coaxed to fight the direction of blood flow, crawling upstream along the walls of veins and arteries.
The in vitro study suggested that this technique could get neutrophils to the sites of infections faster when they are restricted to the direction of blood flow.
Daniel A. Hammer, Alfred G. and Meta A. Ennis Professor in the Department of Bioengineering, and Alexander Buffone, Jr., a research associate in his lab, led the research. Nicholas R. Anderson, a graduate student in the Hammer lab, also contributed to the study.
Nearly four years ago, when Angelica Du was a freshman, she recalled being completely “awestruck” upon walking into her first Scholarship Celebration.
“It’s just really warm,” the now-senior noted at this year’s event, which took place Wednesday, Nov. 20. “My donors have always been so warm with me.”
Du—with a smile that’s constant, as well as contagious—scanned the red-and-blue draped walls of the John R. Rockwell Gymnasium, completely transformed for the yearly event on campus, and eyed the appetizers being passed. She glanced at her proud mom, a few folks over. Hosted by the Undergraduate Named Scholarship Program, the Celebration is one that has grown to attract hundreds of scholarship donors and their recipients and families, for an evening of networking and good-old-fashioned catching up.
“[Angelica] tells me that she’s proud,” said Jerry Riesenbach, a Wharton School alumnus who helped support Du’s cost of education through the Class of 1960 scholarship fund. “And I said to her, she makes us proud. Being able to provide funds is one thing, but seeing the benefit that goes to these young people, who have such tremendous aspirations and are so grateful, is another.”
At Penn, Du, who will graduate with her bachelor’s in bioengineering in May and her master’s in December 2020, designs robots and conducts neurobiology research. She teaches thermodynamics and critical writing to her peers. She sings for a Disney-themed a cappella group, serves her community in a Christian union, celebrates her culture in the Penn Philippine Association, and advocates within several honor societies. This past summer, she worked at Thermo Fisher Scientific, running experiments for a next-generation sequencer that will take a patient’s DNA, sequence it, and diagnose it within 24 hours.
What originally drew me to this field was a “Women in Engineering Day” I attended at a local college while in high school. I had the opportunity to hear incredible women speak about their research regarding biomaterials and tissue engineering. This event showed me the impact this field can have on the world. This drove me to pursue an undergraduate degree in Biomedical Engineering, which only strengthened my passion. As I furthered my studies and began working full-time at a biotechnology company, I learned more about bioengineering. With encouragement from my coworkers and family, I decided to pursue my Master’s in Bioengineering and am delighted to have the opportunity to study at Penn.
What kind of research do you conduct, and what do you hope to focus on for your thesis?
I am actually a part-time student, who works full-time at a drug packaging and medical device company out in Exton, PA. Though I am not doing research on campus, my coursework has tied into previous research projects I have participated in at my job. My latest project entailed understanding different material properties used in container closure systems for mAb-based biologics and how they interact. This work was done to support an understanding of how to pick appropriate vial/syringe systems for various drug products in development.
What’s your favorite thing to do on Penn’s campus or in Philly?
My favorite thing to do is trying all the new restaurants and incredible foods this city has to offer. I think Philadelphia is so unique and has such rich cultural influences. With so many different neighborhoods and restaurant options you really can’t go wrong.
What did you study for your undergraduate degree, how does it pair with the work you’re doing now, and what advice would you give to your undergraduate self?
My undergraduate degree was in Biomedical Engineering. It has supported my graduate coursework very well and has given me a great opportunity to dive deeper into certain parts of my studies.
My advice to my younger self would be to take your time! It took me a little while to evaluate different graduate programs and choose which was right for me. Though it took some time, I ultimately decided what was best for me and couldn’t be happier with my choices.
What are you thinking about doing after graduate school?
Currently, I work full-time as an Associate Packaging Engineer at West Pharmaceutical Services in Exton, PA. I hope to take my degree to further my career and to help support my future aspirations at this company.